Diag2Tec uses a large panel of unique myeloma cell lines derived from patients by our academic partners. These cell lines are patented and, represent the molecular heterogeneity of patients, with more than 6 subgroups described.
human Myeloma
Cell Lines
cell lines derives from Myeloma patients
acquired resistant cell lines
therapeutic agents response tested
Our HMCL collection has been extensively characterized using:
In addition, comprehensive immunophenotypic and cytogenetic analyses have been performed. We have also evaluated the response of HMCLs to a panel of 30+ therapeutic agents, including:
We described with our academic partners the mutational landscape of human myeloma cell lines using whole-exome sequencing (WES) on 30 HMCLs. This study allowed the identification of mutations in key pathways involved in multiple myeloma, including alterations associated with drug resistance.
Furthermore, we have developed human myeloma cell lines with acquired resistance to major therapeutic classes, including proteasome inhibitors, melphalan, HDAC inhibitors, and Venetoclax. These resistant models provide a powerful platform to investigate mechanisms of drug resistance and identify strategies to overcome therapeutic escape.
With these fully characterized cell lines, Diag2Tec offers the opportunity to screen anti-myeloma compounds, explore mechanisms of action, and study drug resistance in clinically relevant models.
Diag2Tec provides services based on a diverse collection of B-cell and T-cell lymphoma cell lines (commercial cell lines)
Diag2Tec provides services based on a diverse collection of B-cell and T-cell lymphoma cell lines (commercial cell lines), including approximately:
- 15+ human Diffuse Large B-Cell Lymphoma (DLBCL) cell lines
- 7 human Mantle Cell Lymphoma (MCL) cell lines
- 8 human T-cell lymphoma cell lines
The majority of these cell lines have been characterized for their response to conventional therapies, enabling the selection of sensitive and resistant models and supporting the evaluation of combination treatments in cytotoxicity assays.
Gene expression profiles and mutational status are available for most of these cell lines, providing valuable molecular insights to support mechanism-of-action studies, biomarker discovery, and translational research
Diag2Tec provides access to a panel of 15+ Acute Myeloid Leukemia (AML) cell lines representing different FAB subgroups, capturing the biological and molecular diversity of AML (commercial cell lines).
Diag2Tec provides access to a panel of 15+ Acute Myeloid Leukemia (AML) cell lines representing different FAB subgroups, capturing the biological and molecular diversity of AML (commercial cell lines).
The majority of these cell lines have been characterized for their response to conventional therapies, enabling the selection of sensitive and resistant models and supporting the evaluation of combination treatments in cytotoxicity assays.
These cell lines are supported by available gene expression profiles and mutational data, enabling the assessment of target expression, identification of relevant mutations, and selection of appropriate models for your studies.